ロード中...
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
Two recently approved PARP inhibitors provide an important new therapeutic option for patients with BRCA-mutated metastatic breast cancer. PARP inhibitors significantly prolong progression-free survival in patients, but conventional oral delivery of PARP inhibitors is hindered by limited bioavailabi...
保存先:
| 出版年: | Theranostics |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ivyspring International Publisher
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6735511/ https://ncbi.nlm.nih.gov/pubmed/31534547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.36281 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|